Last reviewed · How we verify
Early Glargine
Early Glargine is a long-acting basal insulin analog that binds to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in peripheral tissues.
Early Glargine is a long-acting basal insulin analog that binds to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Early Glargine |
|---|---|
| Also known as | lantus |
| Sponsor | The Cleveland Clinic |
| Drug class | Long-acting basal insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Glargine is a recombinant human insulin analog engineered with amino acid substitutions to delay absorption and extend duration of action to approximately 24 hours. It binds to the human insulin receptor with similar affinity to endogenous insulin, activating downstream signaling that increases glucose uptake in muscle and adipose tissue while suppressing hepatic glucose production. The extended half-life allows once-daily dosing for basal insulin replacement in diabetes management.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
Key clinical trials
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis (PHASE2)
- Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management (PHASE4)
- Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes (PHASE4)
- Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis (NA)
- Remission Through Early Monitored Insulin Therapy - Duration Month (PHASE4)
- Early Versus Late Administration of Insulin Glargine in T1DM During Fasting Ramadan (NA)
- Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Early Glargine CI brief — competitive landscape report
- Early Glargine updates RSS · CI watch RSS
- The Cleveland Clinic portfolio CI